Cryptogenic multiterritorial stroke with anti-U1 ribonucleoprotein positivity and steroid responsiveness: a diagnostic challenge
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261366Keywords:
Ischaemic stroke, Multiterritorial infarcts, Autoimmune markers, Anti-U1 RNP, Cerebellar ataxia, CorticosteroidsAbstract
Acute ischemic stroke is most commonly caused by atherosclerotic, cardioembolic, or small vessel disease; however, in patients presenting with multiterritorial infarcts and inconclusive routine evaluation, alternative etiologies such as autoimmune mechanisms should be considered. We report the case of a 52-year-old male who presented with acute-onset vertigo followed by progressive imbalance and left-sided incoordination. Neuroimaging revealed multiple acute infarcts involving both anterior and posterior circulation. Cardiac and vascular evaluation did not identify a definitive source of embolism. Autoimmune workup demonstrated positive antinuclear antibodies with anti-U1 ribonucleoprotein (RNP)/Sm positivity raising suspicion of an underlying autoimmune-mediated process despite the absence of overt systemic features. The patient showed limited improvement with standard antiplatelet therapy but demonstrated marked clinical recovery following corticosteroid therapy, suggesting a possible inflammatory or immune-mediated mechanism. This case highlights the importance of considering autoimmune causes in patients with cryptogenic multiterritorial stroke and suggests a potential role for immunosuppressive therapy in selected cases.
References
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Stroke. 1993;24(1):35-41.
Sanna G, D’Cruz D. Cerebral manifestations in systemic autoimmune diseases. Rheumatology (Oxford). 2003;42(10):1234-45.
Benseler SM, Silverman ED. Systemic vasculitis in children and adults. Lancet. 2006;367(9511):170-81.
Birnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol. 2009;66(6):704-9.
Joseph FG, Scolding NJ. Neurolupus. Pract Neurol. 2010;10(1):4-15.
Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology. 2003;207(1):5-11.
Caplan LR. Brain embolism revisited. Neurology. 1993;43(7):1281-7.
Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke. Stroke. 2001;32(11):2559-66.
Küker W, Gaertner S, Nagele T, Dopfer C, Nägele T, et al. Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis. Cerebrovasc Dis. 2008;26(1):23-9.
Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Huston J 3rd, Meschia JF, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol. 2007;62(5):442-51.
Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, et al. Primary CNS vasculitis: diagnosis and management. Pract Neurol. 2015;15(6):416-27.
Levine SR, Brey RL. The role of antiphospholipid antibodies in stroke. Curr Opin Neurol. 1995;8(1):33-8.